Analysts Set Immunic, Inc. (NASDAQ:IMUX) PT at $12.67

Immunic, Inc. (NASDAQ:IMUX) has been assigned a consensus recommendation of “Buy” from the eight ratings firms that are presently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $12.67.

IMUX has been the topic of a number of analyst reports. D. Boral Capital reissued a “buy” rating and issued a $17.00 target price on shares of Immunic in a research note on Tuesday, January 7th. StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. Finally, HC Wainwright initiated coverage on Immunic in a report on Monday, November 25th. They issued a “buy” rating and a $10.00 target price for the company.

Insider Activity at Immunic

In related news, Director Richard Alan Rudick acquired 87,300 shares of the firm’s stock in a transaction on Tuesday, November 12th. The shares were purchased at an average price of $1.15 per share, with a total value of $100,395.00. Following the acquisition, the director now directly owns 87,300 shares in the company, valued at $100,395. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Immunic

Large investors have recently modified their holdings of the stock. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Immunic by 70.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after purchasing an additional 42,383 shares in the last quarter. Jane Street Group LLC boosted its position in Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after buying an additional 38,553 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Immunic in the 3rd quarter valued at $50,000. Finally, State Street Corp raised its position in shares of Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after acquiring an additional 11,642 shares during the last quarter. 51.82% of the stock is currently owned by institutional investors and hedge funds.

Immunic Price Performance

IMUX opened at $1.00 on Friday. Immunic has a fifty-two week low of $0.97 and a fifty-two week high of $2.11. The company has a market capitalization of $90.08 million, a P/E ratio of -0.81 and a beta of 1.88. The firm’s fifty day moving average price is $1.13 and its two-hundred day moving average price is $1.32.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.